JUL 22, 2016 08:04 AM PDT

Antipsychotic Drug Reduces Nausea, Vomiting Caused By Chemo

Nausea and vomiting are among the most common adverse side effects of chemotherapy. In fact, some drugs induce such severe nausea and vomiting that some patients can’t tolerate it all. Now researchers from Sanford Health say that a common antipsychotic drug reduces and may even prevent this nasty side effect in patients undergoing chemotherapy. The discovery could be a game-changer in the quality of life for these patients.

Antipsychotic drug makes huge difference in chemo-induced nausea | Image : healthawarenessforall.com

"We've long known the nausea and vomiting that come along with chemotherapy are a major problem and affect the quality of life of our patients," said Steven Powell, co-author of the study. Among the chemotherapy drugs that have the highest likelihood of causing nausea and vomiting are commonly prescribed ones like cisplatin (Platinol), doxorubicin (Adriamycin), and etoposide (Etopophos).

The drug is known as olanzapine (Zyprexa), and was first approved by the Food and Drug Administration in early 2000 for the treatment of bipolar I disorder, and for schizophrenia. The drug is a dopamine antagonist with a structure similar to clozapine, another atypical antipsychotic used to treat schizophrenia.

Previous clinical trials (Phase I and II) with olanzapine already showed that the drug was safe and efficacious at controlling chemotherapy-induced nausea and vomiting (CINV). The current trial tested whether olanzapine would truly benefit patients. In this study, the Sanford team followed 380 patients undergoing chemotherapy. About half of the patients (192) were paired with olanzapine, while the other half (188) were paired with a placebo treatment.

Within 24 hours after chemotherapy, the team reported that 74 percent of patients given olanzapine had no nausea or vomiting. By contrast, only about half of the placebo group reported the same outcome. Furthermore, the antiemetic benefits of olanzapine appeared to be sustained. When researchers analyzed patients at between days 1-5, and at day 5, the olanzapine group still fared better in terms of preventing nausea and vomiting.
The team reported no grade 5 toxic effects, though some patients in the olanzapine group had increased sedation on day 2.

“Olanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy,” the researchers wrote in their study.

The encouraging results from this trial, along with the fact that the drug is already FDA-approved could mean olanzapine may come to the chemotherapy clinic soon. Even more promising is that the first generic olanzapine was approved in 2011, which means chemotherapy patients can reduce nausea side effects at reduced costs. "The findings of this study, fortunately, provide physicians with a tool to better address the needs of those they are treating for cancer," said Powell.

Additional source: Sanford Health press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 25, 2018
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
AUG 14, 2018
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
SEP 26, 2018
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 17, 2018
Cell & Molecular Biology
OCT 17, 2018
Saving Patients From Unnecessary Chemotherapy with a Blood Test
Often, cancer patients get chemotherapy after surgery to ensure that their cancer will not come back; for many it's not needed....
OCT 21, 2018
OCT 21, 2018
New Technology Detects Early-Stage Lung Cancer
According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be impr...
NOV 12, 2018
NOV 12, 2018
Targeted radiation therapy may provide new hope to children with difficult-to-treat liver cancer
Primary malignant liver tumors are rare in children with an occurrence rate of 1-2% of all childhood cancers. Radical surgical resection of the liver which means the removal of part of the li...
Loading Comments...